Aplastic anemia (AA) — acquired SAA/VSAA + inherited bone marrow failure (Fanconi, DC, DBA, SDS)

What changes during this transition

Aplastic anemia (AA) is a bone marrow failure syndrome defined by pancytopenia and a hypocellular bone marrow. The clinical population sits across two distinct but overlapping populations a peptide companion needs to engage honestly. Acquired AA is the most common — immune-mediated destruction of hematopoietic stem cells by autoreactive T cells, idiopathic in the majority of cases, with a minority traceable to drug or toxin exposure (chloramphenicol, benzene, gold, antiepileptics, some NSAIDs); seronegative hepatitis-associated AA is a distinct subset. Inherited bone marrow failure syndromes (IBMFS) overlap clinically and biologically and are often pediatric onset: Fanconi anemia (FA, autosomal recessive in most subtypes, biallelic FANC pathway mutations, DNA crosslink repair defect with diagnostic mitomycin C chromosomal breakage test, characteristic congenital anomalies including radial-ray, café-au-lait, short stature, increased solid tumor and AML risk), Dyskeratosis congenita (DC, telomere biology disorders with TERT, TERC, DKC1, TINF2, RTEL1 mutations, classic mucocutaneous triad of dystrophic nails, oral leukoplakia, reticular pigmentation, pulmonary fibrosis and hepatic disease in adults), Diamond-Blackfan anemia (DBA, ribosomopathy with heterozygous mutations in RPS19 and other ribosomal genes, pure red cell aplasia with characteristic congenital anomalies including short stature, craniofacial, thumb), and Shwachman-Diamond syndrome (SDS, biallelic SBDS mutations with exocrine pancreatic insufficiency, skeletal anomalies, and marrow failure). AA-PNH is a recognized bidirectional overlap entity — patients move between diagnoses, and high-sensitivity flow cytometry with FLAER + CD55 + CD59 on granulocytes is part of every AA workup. Severity is anchored by Camitta criteria: severe AA (SAA) = hypocellular marrow plus at least two of ANC <500, platelets <20K, reticulocyte count <60K; very severe AA (VSAA) = ANC <200. Disease-modifying peptide/protein therapy in AA is named by drug. Allogeneic hematopoietic stem cell transplantation (HSCT) remains the only curative therapy — first-line for SAA in patients under 50 with a matched sibling donor, with matched unrelated donor (MUD) increasingly used in younger patients in the front-line setting, and haploidentical transplant with post-transplant cyclophosphamide protocols expanding access globally. Immunosuppressive therapy (IST) has been the non-transplant backbone since the 1990s: horse ATG (hATG, lymphoglobulin) plus cyclosporine A (CsA), with rabbit ATG reserved for relapse given inferior front-line response. ELTROMBOPAG (Promacta in the US, Revolade ex-US, Novartis) is a thrombopoietin receptor agonist that transformed AA outcomes — FDA-approved November 2014 for refractory SAA after IST failure, then expanded January 2018 to front-line SAA in combination with hATG plus CsA based on the NIH Clinical Center RACE trial cohort; combined response rate of approximately 85% vs approximately 60% for IST alone reshaped the standard-of-care conversation. ROMIPLOSTIM (Nplate, Amgen) is a TPO mimetic peptibody approved for thrombocytopenia indications with emerging role in AA. For inherited BMF syndromes, the disease-modifying therapies differ by syndrome: Fanconi anemia treated with allogeneic HSCT (curative for the hematologic component, with reduced-intensity conditioning regimens designed for the DNA-repair defect background), with gene therapy programs in trials (Rocket Pharmaceuticals RP-L102 for Fanconi A); Dyskeratosis congenita treated supportively with HSCT for marrow failure; Diamond-Blackfan anemia treated first-line with corticosteroids, HSCT curative, and L-leucine plus lenalidomide as emerging approaches; Shwachman-Diamond treated with pancreatic enzyme replacement and HSCT for the marrow failure component. International transplant registries — EBMT (European) and CIBMTR (US/international) — anchor the cross-jurisdictional evidence base. Patient advocacy is coordinated through AAMDSIF (aamds.org), the Fanconi Anemia Research Fund (FARF, fanconi.org), the DBA Foundation, Dyskeratosis Congenita Outreach, and the International Severe Aplastic Anemia Foundation (ISAAF). No peptide in the Juno library has a discovery-card-defensible AA case. The load-bearing safety thread is sharper here than for most substrates: SC injection in patients with profound thrombocytopenia (platelets <20K is a clinical reality in SAA, not a theoretical edge case) is a genuine bleed-risk event, and SC injection in patients with profound neutropenia (ANC <500 is the population AA defines) is a genuine injection-site infection risk in the dominant cause-of-death pattern for AA. BPC-157's SC injection plus pro-angiogenic mechanism uncharacterized in bone marrow failure is the sharpest mechanism-vs-disease editorial collision. NMN reaches AA through the aging-AA-survivor demographic that emerged from the eltrombopag transformation. The GH-axis trio intersects pediatric inherited BMF short stature (Fanconi and DBA) where somatropin under pediatric endocrinology supervision is the supervised pathway; Rule 6 non-propagation is sharpest for tesamorelin. Semaglutide is the coordination-of-care conversation for long-term IST + eltrombopag survivors and post-HSCT metabolic syndrome from chronic GVHD and steroid burden. Eighty-ninth deliberate non-elevation.